benalex pharmaceuticals, inc.

131 brush hollow crescent
rye brook, new york 10573

NYS Entity Status
ACTIVE

NYS Filing Date
NOVEMBER 01, 2013

NYS DOS ID#
4481602

County
WESTCHESTER

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC BUSINESS CORPORATION

Name History
2013 - BENALEX PHARMACEUTICALS, INC.









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • A Deli Where Rye Comes in Slices and in a Glass
    By ROBERT SIMONSON - Wednesday Nov 15, 2017

    A branch of the Second Avenue Deli is opening an upstairs bar where you can raise a toast (using a Dr. Brown’s) to Jewish culture.

    Source: NYT > Home Page
  • What to Do When You’ve Picked the Wrong Suburb
    By BROOKE LEA FOSTER - Friday Jul 28, 2017

    After leaving the city, some people discover that the first town they choose isn’t quite right and they have to search for a place that is a better fit.

    Source: NYT > Home Page
  • A Drug Maker Spends Big in Washington to Make Itself Heard
    By JAY HANCOCK, ELIZABETH LUCAS and SYDNEY LUPKIN - Friday Jul 21, 2017

    Mallinckrodt’s spending on political donations and lobbying comes as the drug industry as a whole beefs up its Capitol Hill presence.

    Source: NYT > Home Page
  • Impax Laboratories and Amneal Pharmaceuticals Near Merger Agreement
    Monday Oct 16, 2017

    Impax Laboratories Inc. and Amneal Pharmaceuticals LLC are close to agreement on a merger that would create the nation’s fifth-largest generic-drug company by revenue, according to people familiar with the matter.

    Source: The Wall Street Journal: U.S. Business
  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy VC, Deals, & Startups Feed